866-997-4948(US-Canada Toll Free)

Tyvaso (treprostinil)- Analysis and Estimates from 2009 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 30 Pages


GlobalDatas pharmaceuticals report, Tyvaso (treprostinil)Analysis and Estimates from 2009 to 2020 provides Tyvaso sales estimates for US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Tyvaso including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Tyvaso including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2009-2020 for Tyvaso in the US
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Pulmonary Arterial Hypertension 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 5
2.3 Etiology 5
2.3.1 Scleroderma 5
2.3.2 Sickle Cell Disease 5
2.3.3 HIV/AIDS 5
2.3.4 Drug Abuse and Toxins 5
2.4 Economic Impact of PAH 5
2.5 GlobalData Report Guidance 6

3 Pulmonary Arterial Hypertension (PAH): Market Characterization 7
3.1 PAH Market 7
3.2 PAH Market Forecasts and CAGR 8
3.3 PAH Market : Drivers and Restraints 8
3.3.1 Drivers 9
3.3.2 Barriers 10

4 Classification of PAH 11
4.1 Classification Based on Cause and Clinical Presentation 11
4.1.1 Idiopathic PAH 11
4.1.2 Familial PAH 11
4.1.3 Drug Induced PAH 11
4.1.4 PAH Associated with Other Conditions 11
4.1.5 PAH Associated with Significant Venous or Capillary Involvement 11
4.2 Symptomatic Profile of PAH 11

5 Evolution of PAH Treatments 12

6 Medications 13
6.1 Prostanoids 13
6.1.1 Epoprostenol 13
6.1.2 Treprostinil 13
6.1.3 Iloprost 13
6.1.4 Beraprost 13
6.2 Endothelin Receptor Antagonists 13
6.2.1 Bosentan 13
6.2.2 Ambrisentan 14
6.2.3 Sitaxsentan 14
6.3 Phosphodiesterase Type 5 Inhibitors 14
6.3.1 Sildenafil 14
6.3.2 Tadalafil 14
6.4 Surgical Treatments 14
6.5 Investigational Combination Regimens 15
6.6 New Targets for PAH Therapy 15

7 Market Share by Class in PAH 17

8 Tyvaso (treprostinil) 18
8.1 Introduction 18
8.2 Mechanism of Action 18
8.3 Clinical Studies 18
8.3.1 Triumph I 18
8.4 Approval History of Tyvaso 19
8.5 Factors Affecting Sales of Tyvaso 20
8.5.1 Dosing Convenience of Tyvaso over Ventavis 20
8.5.2 Switching from Ventavis to Tyvaso 20
8.5.3 Increasing Market Share of Tyvaso 20
8.5.4 Improved Dosing Compliance 20
8.5.5 Tyvaso Handling over Ventavis 20
8.6 Drug Evaluation 20
8.6.1 Drug Risk Benefit Score 20
8.6.2 Intensity of Competition 21
8.7 Sales Estimates 22
8.7.1 Target Patient Pool for Tyvaso 22
8.7.2 Dosing 22
8.7.3 Market Penetration 22
8.7.4 Annual Cost of Therapy 23
8.7.5 Sales Projections of Tyvaso 24

9 PAH Market: Appendix 25
9.1 Market Definitions 25
9.2 List of Abberiviations 25
9.3 Research Methodology 26
9.3.1 Coverage 26
9.3.2 Secondary Research 26
9.3.3 Forecasting 26
9.3.4 Number of Patients Approved to take the Drug 27
9.3.5 Net Penetration of Drug 27
9.3.6 Net Annual Dosing 28
9.3.7 Annual Cost of Therapy 28
9.3.8 Primary Research 28
9.3.9 Expert Panels 28
9.4 Drug Sales Estimates Model 28
9.5 Contact Us 29
9.6 Disclaimer 29
9.7 Sources 29

List of Table


Table 1: PAH, Global, Major Marketed Drugs 7
Table 2: PAH, Global, Pipeline (Phase III) 8
Table 3: PAH Drugs Evolution 12
Table 4: Approval of Tyvaso 19
Table 5: Drug Risk Benefit Score 21
Table 6: Common Adverse Events in

List of Chart


Figure 1: PAH, Global, Market Size Forecasts ($bn), 20102020 8
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010 17
Figure 3: Change from Baseline in 6-Minute Walk Distance (meter) at Week 12 during Plasma Concentration 18
Figure 4: Placebo Corrected Change From Baseline in 6-Minute Walk Distance (meters) by Study Subpopulation: Mean (95% Confidence Interval) 19
Figure 5: Drug Model Diagram of Tyvaso 22
Figure 6: Tyvaso, PAH, The US, Sales Estimates ($m), 2009-2020 24
Figure 7: Drug Model Diagram 27
Figure 8: Patients Approved for the Drug 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *